Active Filter(s):
Details:
Relief Therapeutics and AdVita Lifescience are set to enrol the first patient in a Phase II trial of an inhaled formulation of the former’s lead compound, RLF-100 (aviptadil), for preventing Covid-19-related acute respiratory distress syndrome (ARDS).
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyesami
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Recipient: Relief Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
Relief will gain further pending intellectual property rights that may cover RLF-100TM inhaled formulation specifications and the potential application of inhaled Aviptadil in the treatment of Acute Respiratory Distress Syndrome and Checkpoint Inhibitor-induced Pneumonitis.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Relief Therapeutics
Deal Size: $2.4 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 20, 2021